AVXL Stock Forecast: Anavex Life Sciences Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.59
−11.45% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 20 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$61.9M
Ticker Nerd rank
20/ 100
Median analyst target
$20
Analysts covering
—
Revenue$0.0
Operating income$6.8M
Net income$7.8M
Free cash flow−$9.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−36.7%
1M
−56.5%
YTD
−83.4%
1Y
−81.3%
From 52W high
−88.8%
From 52W low
0.0%
$0.59
$5.30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Anavex Life Sciences Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
20/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
84
Quality
64
Issuance
41
Volatility
25
Revisions
20
Value
13
Accruals
11
Momentum
7

Growth (84): Sales and profits are climbing, and climbing faster than before.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AVXL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVXL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26AVXLHigh $20Median $20Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Mar 2026D. Boral CapitalMaintainsBuy$24
26 Mar 2026D. Boral CapitalMaintainsBuy$24
23 Mar 2026D. Boral CapitalMaintainsBuy—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
9 Feb 2026D. Boral CapitalMaintainsBuy—
6 Jan 2026D. Boral CapitalMaintainsBuy—
19 Dec 2025D. Boral CapitalMaintainsBuy—
19 Dec 2025HC Wainwright & Co.ReiteratesBuy—
15 Dec 2025D. Boral CapitalMaintainsBuy—
28 Nov 2025HC Wainwright & Co.ReiteratesBuy—
26 Nov 2025D. Boral CapitalMaintainsBuy—
19 Nov 2025HC Wainwright & Co.MaintainsBuy—
14 Nov 2025D. Boral CapitalMaintainsBuy—
29 Oct 2025D. Boral CapitalMaintainsBuy—
24 Oct 2025Jones TradingDowngradeHold—
7 Oct 2025HC Wainwright & Co.ReiteratesBuy—
2 Oct 2025D. Boral CapitalMaintainsBuy—
1 Oct 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AVXL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AVXL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Anavex Life Sciences Corp. returned −81.3% against +6.9% for the S&P 500, dividends included.

AVXL vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26AVXLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AVXL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.6×

Cheaper than 84% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−12.8%

Higher than 35% of US stocks

Return on assets
−9.7%

Higher than 27% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Anavex Life Sciences Corp. has a market value of $61.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$13.0M.

  • Diluted earnings per share, trailing twelve months: −$0.15.

  • Free cash flow in the twelve months to 30 June 2026: −$29.3M.

  • Shares outstanding: 92.7M.

  • Anavex Life Sciences Corp. employs 34 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

AVXL and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AVXLAnavex Life Sciences Corp.$61.9M20
BOLDBoundless Bio, Inc.$54.8M93
OKYOOKYO Pharma Ltd.$55.0M26
AZRAzora Therapeutics, Inc.$55.0M16
NORDNordicus Partners Corp.$54.4M25
CHRSCoherus Oncology, Inc.$55.3M38
CGTXCognition Therapeutics, Inc.$55.4M47

Take a look at AVXL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Anavex Life Sciences Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about AVXL

How does Ticker Nerd's model rank AVXL?

As at 21 Nov 2026, Anavex Life Sciences Corp. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (84 of 100).

What is the AVXL stock forecast for 2030?

No analyst covering Anavex Life Sciences Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVXL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

How has AVXL stock performed over the past year?

Anavex Life Sciences Corp. returned -81.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Anavex Life Sciences Corp. do?

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing oral therapies for central nervous system disorders. Its current pipeline targets conditions such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other neurodegenerative, neurodevelopmental, and neuropsychiatric diseases.

Company

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing oral therapies for central nervous system disorders. Its current pipeline targets conditions such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other neurodegenerative, neurodevelopmental, and neuropsychiatric diseases. The company’s work centers on precision medicine approaches designed to address high unmet medical needs in brain health, with a primary emphasis on advancing candidate medicines through clinical development. Anavex Life Sciences Corp. operates in the biotechnology sector and serves as a research-driven participant in the global pharmaceutical market, where it contributes to the development of potential treatments for complex neurological diseases.

CEO Dr. Terrie Kellmeyer Ph.D. · 34 employees · United States · https://www.anavex.com